Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements

  title={Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements},
  author={Chung-Jr Huang and Henry Lin and Xiaoming Yang},
  journal={Journal of Industrial Microbiology \& Biotechnology},
Nearly 30% of currently approved recombinant therapeutic proteins are produced in Escherichia coli. Due to its well-characterized genetics, rapid growth and high-yield production, E. coli has been a preferred choice and a workhorse for expression of non-glycosylated proteins in the biotech industry. There is a wealth of knowledge and comprehensive tools for E. coli systems, such as expression vectors, production strains, protein folding and fermentation technologies, that are well tailored for… 

Production and Purification of Recombinant Proteins from Escherichia coli

The bioproducts obtained after fermentation and purification processes may fulfill the requirements for the development of various diagnostics, therapeutics, or prophylactic agents against different kinds of diseases.

Current trends in biopharmaceuticals production in Escherichia coli.

A review of the contribution that this model organism has made in the production of new biotech products for human medicine will include new advancements in the E. coli expression system to meet the biotechnology industry requirements, such as novel engineered strains to glycosylate heterologous proteins, add disulphide bonds and express complex proteins.

Recent Improvements in Production of Recombinant Proteins

Using systems biology and applying engineering principles for optimization and development of biological systems are effective strategies, that using them in the development of recombinant protein production process-es is increasing rapidly.

Advanced technologies for improved expression of recombinant proteins in bacteria: perspectives and applications

An impression of expression technologies developed in recent times for enhanced production of heterologous proteins in E. coli are provided, which are of foremost importance for diverse applications in microbiology and biopharmaceutical production.

Full-length recombinant antibodies from Escherichia coli: production, characterization, effector function (Fc) engineering, and clinical evaluation

This review summarizes recent research, preclinical advancements, and clinical development of E. coli-produced aglycosylated therapeutic antibodies as monoclonal, bispecific, and antibody-drug conjugates for use in autoimmune, oncology, and immuno-oncology areas.

Development of innovative screening procedures and fermentation processes for the production of recombinant proteins in E. coli

The generation of mutant signal peptide libraries in combination with the β-lactamase screening assay represents an important advance for the production of disulphide bonded proteins for the biotechnology industry.

Recent Developments in Bioprocessing of Recombinant Proteins: Expression Hosts and Process Development

Recently, advances have been made in the various areas of bioprocessing and are being utilized to develop effective processes for producing recombinant proteins that can be used as therapeutics, vaccines, and diagnostic reagents.

Environmental and recombinant microorganisms for biopharmaceuticals production

The current application of microbes as production platforms for recombinant proteins and its genetic engineering for the use as biopharmaceuticals is presented.

Advances in recombinant protein expression for use in pharmaceutical research.




Extracellular recombinant protein production from Escherichia coli

This review provides an overview of recent developments in engineering E. coli for extracellular production of recombinant proteins and an analysis of pros and cons of each strategy.

Manufacturing of recombinant therapeutic proteins in microbial systems

Current applications and trends for development, production and analytical characterization of recombinant therapeutic proteins in microbial systems, including E. coli, are summarized.

Engineering of Therapeutic Proteins Production in Escherichia coli

  • M. Kamionka
  • Biology, Engineering
    Current pharmaceutical biotechnology
  • 2011
This article presents a variety of examples of genetic engineering of therapeutic proteins and emphasizes the importance of designing a construct without any unnecessary amino acid residues.

RETRACTED ARTICLE: Strategies for efficient production of heterologous proteins in Escherichia coli

In recent years, the number of recombinant proteins used for therapeutic applications has increased dramatically, and production of these proteins has a remarkable demand in the market, with major challenges is obtaining the high yield of protein at low cost.

Use of folding modulators to improve heterologous protein production in Escherichia coli

This review critically evaluates the performance of molecular chaperones and folding catalysts native to E. coli in improving functional production of heterologous proteins in the bacterium and discusses how they might best be exploited to provide increased amounts of correctly-folded, active protein for biochemical and biophysical studies.

Understanding the art of producing protein and nonprotein molecules in Escherichia coli

This review presents a compilation of the basic issues that influence the success in the production of protein and nonprotein products in Escherichia coli, as well as some general strategies designed to facilitate downstream process operations and improve biosynthesis yields.

High Yield Production of Heterologous Proteins with Escherichia coli

The fermentation process for high yield scalable production of heterologous recombinant proteins in Escherichia coli is reviewed, and influence of process parameters for the standard fermentation processes are discussed, and alternative methods that solve the limitations are reviewed.

Microbial factories for recombinant pharmaceuticals

The entering into the market of a progressively increasing number of protein drugs produced in non-microbial systems has not impaired the development of products obtained in microbial cells, proving the robustness of the microbial set of cellular systems developed for protein drug production.

Secretory and extracellular production of recombinant proteins using Escherichia coli

  • J. ChoiS. Y. Lee
  • Biology, Engineering
    Applied Microbiology and Biotechnology
  • 2004
Recent advances in secretory and extracellular production of recombinant proteins using E. coli are discussed, including the twin-arginine translocation system, which has recently been employed for the efficient secretion of folded proteins.

Production of recombinant proteins in Escherichia coli

The present review will deal with E. coli as protein factory and will cover some of the aspects related to transcriptional and translational expression signals, factors affecting protein stability and solubility and targeting of proteins to different cell compartments.